{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:54Z","timestamp":1740144234537,"version":"3.37.3"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Heilongjiang Provincial Health and Family Planning Commission Research Project","award":["2014-246"],"award-info":[{"award-number":["2014-246"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Over the past years, ixazomib has been increasingly explored for the treatment of relapsed\/refractory multiple myeloma (RRMM). However, its results are still contradictory. This study will explore the efficacy and safety of ixazomib for patients with RRMM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic records search of Cochrane Library, PUBMED, EMBASE, CINAHL, ACMD, PsycINFO, WANGFANG, and China National Knowledge Infrastructure will be carried out from their origin to March 31, 2020 with no limitations of language and publication status. Trials will be selected by titles\/abstracts, and full manuscripts by 2 independent authors. Data collection will be carried out from eligible trials based on the previous designed criteria. Study quality will be checked using Cochrane risk of bias, and statistical analysis will be administered by RevMan 5.3 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This study will summarize the current high-quality trials investigating the efficacy and safety of ixazomib for the treatment of patients with RRMM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this study may provide convinced evidence on the evidence-based medicine level, and guidance for clinical practice and future studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INPLASY Registration Number:<\/jats:title>\n            <jats:p>INPLASY202040027.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020211","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:57:00Z","timestamp":1589903820000},"page":"e20211","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of ixazomib for the treatment of relapsed\/refractory multiple myeloma"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1533-4893","authenticated-orcid":false,"given":"Zhi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13643-018-0785-7","article-title":"Evidence-based guidelines for physiotherapy management of patients with multiple myeloma: study protocol","volume":"7","author":"Jeevanantham","year":"2018","journal-title":"Syst Rev"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R5-20240521","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CAD.0b013e32836032d5","article-title":"Continuous treatment with new agents for newly diagnosed multiple myeloma","volume":"24","author":"Zou","year":"2013","journal-title":"Anti-Cancer Drugs"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1078155218788706","article-title":"Incidence and management of adverse events associated with panobinostat in the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Moore","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/14656566.2017.1340942","article-title":"Current and developing synthetic pharmacotherapy for treating relapsed\/refractory multiple myeloma","volume":"18","author":"Podar","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-40320-5_10","article-title":"Treatment of relapsed\/refractory multiple myeloma","volume":"169","author":"Neri","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"34001","DOI":"10.18632\/oncotarget.16987","article-title":"Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am J Hematol"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-017-0524-3","article-title":"Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: clinical and model-based analyses","volume":"12","author":"Gupta","year":"2017","journal-title":"Target Oncol"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.30892","article-title":"A phase 1 and 2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"123","author":"Shah","year":"2017","journal-title":"Cancer"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00432-017-2504-5","article-title":"Lenalidomide in combination with bendamustine and prednisolone in relapsed\/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)","volume":"143","author":"Beck","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/bjc.2017.302","article-title":"A phase I\/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma","volume":"117","author":"Cavenagh","year":"2017","journal-title":"Br J Cancer"},{"key":"R17-20240521","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients\u2019 selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/fon-2018-0492","article-title":"Plitidepsin: a potential new treatment for relapsed\/refractory multiple myeloma","volume":"15","author":"Leisch","year":"2019","journal-title":"Future Oncol"},{"key":"R20-20240521","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.727.727","article-title":"Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 study (NCT01564537)","volume":"126","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"R21-20240521","first-page":"2399","article-title":"Safety and management of adverse events of ixazomib\/lenalidomide\/dexamethasone therapy in Japanese patients with relapsed\/refractory multiple myeloma","volume":"59","author":"Iida","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.15679","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar","year":"2019","journal-title":"Br J Haematol"},{"key":"R23-20240521","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13696998.2018.1474745","article-title":"Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed\/refractory multiple myeloma","volume":"21","author":"Hari","year":"2018","journal-title":"J Med Econ"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/JBM.S102328","article-title":"New developments in the management of relapsed\/refractory multiple myeloma - the role of ixazomib","volume":"8","author":"Richardson","year":"2017","journal-title":"J Blood Med"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Mateos","year":"2017","journal-title":"Haematologica"},{"key":"R26-20240521","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R27-20240521","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14733","article-title":"Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br J Haematol"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s10637-016-0346-7","article-title":"Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma: dose selection for a phase 3 maintenance study","volume":"34","author":"Gupta","year":"2016","journal-title":"Invest New Drugs"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R30-20240521","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R31-20240521","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4067\/s0034-98872017001101463","article-title":"Clinical guidelines using the GRADE system (grading of recommendations assessment, development and evaluation)","volume":"145","author":"Mendoza","year":"2017","journal-title":"Rev Med Chil"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:10:55Z","timestamp":1716322255000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020211"}},"subtitle":["A protocol of systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":30,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020211","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}